Topical tranexamic acid for pigmentation: promising, route-specific evidence

Quick answer

Topical tranexamic acid has promising but heterogeneous melasma evidence. Oral, injected and topical routes are not interchangeable. Oral use is a medical decision with systemic risk screening—not a skincare shortcut.

Route is part of the ingredient identity

Tranexamic acid began as a systemic antifibrinolytic medicine. Melasma research now spans oral tablets, injections, microneedling-assisted delivery and topical products. Grouping those into one “TXA works” claim erases clinically important differences.

A 2024 meta-analysis included 22 randomised trials across routes and reported heterogeneity in treatments and adverse effects. ^{Meta-analysis} Another route-focused analysis found that topical evidence remained uncertain against adjuvant comparisons at several measured points. ^{Route analysis}

A cosmetic serum still needs product-level evidence

The ingredient list does not reveal concentration, vehicle, delivery or whether the formula matches a studied topical. Combination formulas also make it difficult to assign any observed change to tranexamic acid alone.

Keep oral treatment outside routine building

Layer & Strand does not provide oral tranexamic-acid selection, dose or screening guidance. Systemic use requires a clinician to consider the diagnosis, contraindications, medicines and clotting-related risk.

What we could not verify

We cannot infer topical effectiveness from oral data, classify every Indian cosmetic containing tranexamic acid or establish long-term benefit from the ingredient name alone.

Bottom line

Topical tranexamic acid is worth understanding, not universalising. Keep the evidence route-specific and suspected melasma clinician-confirmed before moving toward systemic or procedural treatment.